Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Targeting DNA repair vulnerabilities to eradicate TP53 mutated AML.

View Full Paper
Ask AI
Bookmark
Share

Authors

RNRifat Ara NajninJHJian HuangTSTomasz Skórski

Discussion

Loading...

Member takes

Overview

Crispr/Cas9 screening identifies DNA repair pathways in TP53 mutated AML, suggesting melphalan and RAD51 inhibitors may improve outcomes.

Key Points

  • To investigate DNA repair mechanisms in TP53 mutated AML and identify potential therapeutic vulnerabilities.
  • Conducted Crispr/Cas9 screening of 365 DNA damage response genes
  • Performed RNAseq analysis of 1,800 DNA damage response-related genes
  • Executed a drug sensitivity screen on 15 DDR inhibitors
  • RAD51 was identified as a key protein promoting homologous recombination repair in TP53 mutated AML
  • TP53 mutated AML exhibited hypersensitivity to RAD51 inhibitors compared to TP53 wild-type
  • The combination of melphalan and RAD51 inhibitors showed strong inhibitory effects on TP53 mutated AML cells.

Cite This Study

Najnin et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dce5https://doi.org/10.1182/blood-2025-1498
View Full Paper
Ask AI
Bookmark
Share